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Background
The role of the NO-cGMP-PKG pathway in myocardial
protection and preconditioning has been object of inten-
sive investigations. The novel NO- and haem-independ-
ent soluble guanylate cyclase (sGC)-activator cinaciguat
(BAY 58-2667), has been reported to elevate intracellular
cGMP concentration and activate the NO-cGMP-PKG
pathway in vivo. We investigated the effects of cinaciguat
on myocardial infarction (MI) induced by isoproterenol
in rats.
Materials and methods
Rats were treated orally twice a day for 4 d with vehicle or
cinaciguat (10 mg/kg). Isoproterenol (85 mg/kg) was
injected subcutaneously 2 d after the first treatment at an
interval of 24 h for 2 d to produce MI. After 17 h, his-
topathological examination of heart tissue was performed
and plasma lactate dehdyrogenase (LDH) activity, thio-
barbituric acid reactive substances (TBARS) were meas-
ured. We performed left ventricular pressure-volume (PV)
analysis to assess cardiac function using a microtip Millar
PV conductance catheter. Expression of different genes
was analysed by quantitative real time PCR. Isolated
canine coronary arterial rings exposed to peroxynitrite
were investigated for vasomotor function and immuno-
histochemistry was performed for cGMP and nitrotyro-
sine (NT).
Results
The present results show that cinaciguat treatment
improves cardiac performance (showed by increased
load-independent, PV loops derived contractility
indexes), improves impaired cardiac relaxation (as
reflected by prolonged time constant of pressure decay),
and improves histopathological lesions. Cinaciguat also
reduces oxidative stress (showed by decreased level of
TBARS), ameliorates intracellular enzyme release (as evi-
denced by decreased LDH activity), decreases COX-2,
TGF-β and β-actin mRNA expression in experimental MI
in rats. In vitro exposure of coronary arteries to peroxyni-
trite resulted in an impairment of endothelium-depend-
ent vasorelaxation (showed by reduced maximal
relaxation to acetylcholine), increased nitro-oxidative
stress and reduced intracellular cGMP levels (as demon-
strated by higher NT- and lower cGMP-immunoreactivity)
which were all improved by cinaciguat incubation of cor-
onary arterial rings.
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Conclusion
Pharmacological sGC activation could be a novel
approach for prevention and treatment of ischemic heart
disease.